Beam Price Fair Value from 2010 to 2024

BEAM Stock  USD 23.58  0.91  3.72%   
Beam Therapeutics Price Fair Value yearly trend continues to be very stable with very little volatility. Price Fair Value is likely to grow to 2.25 this year. During the period from 2010 to 2024, Beam Therapeutics Price Fair Value quarterly data regression pattern had sample variance of  1,115 and median of (58.06). View All Fundamentals
 
Price Fair Value  
First Reported
2010-12-31
Previous Quarter
2.14002766
Current Value
2.25
Quarterly Volatility
33.39858941
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Beam Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Beam Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.7 M, Interest Expense of 49 M or Selling General Administrative of 122.7 M, as well as many indicators such as Price To Sales Ratio of 5.28, Dividend Yield of 0.0106 or PTB Ratio of 2.25. Beam financial statements analysis is a perfect complement when working with Beam Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Beam Therapeutics Correlation against competitors.
To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.

Latest Beam Therapeutics' Price Fair Value Growth Pattern

Below is the plot of the Price Fair Value of Beam Therapeutics over the last few years. It is Beam Therapeutics' Price Fair Value historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Beam Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Price Fair Value10 Years Trend
Slightly volatile
   Price Fair Value   
       Timeline  

Beam Price Fair Value Regression Statistics

Arithmetic Mean(28.01)
Geometric Mean18.53
Coefficient Of Variation(119.23)
Mean Deviation32.05
Median(58.06)
Standard Deviation33.40
Sample Variance1,115
Range73.5977
R-Value0.85
Mean Square Error342.22
R-Squared0.72
Significance0.000071
Slope6.32
Total Sum of Squares15,617

Beam Price Fair Value History

2024 2.25
2023 2.14
2022 3.73
2021 6.19
2020 15.54
2019 9.54
2018 4.92

About Beam Therapeutics Financial Statements

Beam Therapeutics investors utilize fundamental indicators, such as Price Fair Value, to predict how Beam Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Price Fair Value 2.14  2.25 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Beam Therapeutics is a strong investment it is important to analyze Beam Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Beam Therapeutics' future performance. For an informed investment choice regarding Beam Stock, refer to the following important reports:
Check out the analysis of Beam Therapeutics Correlation against competitors.
To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.58)
Revenue Per Share
4.273
Quarterly Revenue Growth
(0.17)
Return On Assets
(0.09)
Return On Equity
(0.18)
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.